Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0001104659-19-040969

Options or other derivatives

  • Director acquired 9,285 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Haviland Kate Director 2019-07-18 Grant or award · Stock Option (right to buy) +9,285 9,285 D: show line 1 in the form
Loading xslF345X03/a4.xml…